IL150127A0 - Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy - Google Patents

Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy

Info

Publication number
IL150127A0
IL150127A0 IL15012700A IL15012700A IL150127A0 IL 150127 A0 IL150127 A0 IL 150127A0 IL 15012700 A IL15012700 A IL 15012700A IL 15012700 A IL15012700 A IL 15012700A IL 150127 A0 IL150127 A0 IL 150127A0
Authority
IL
Israel
Prior art keywords
therapy
oxycodon
active ingredient
oral cavity
transmucosal administration
Prior art date
Application number
IL15012700A
Other languages
English (en)
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IL150127A0 publication Critical patent/IL150127A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15012700A 1999-12-14 2000-12-01 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy IL150127A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19960154A DE19960154A1 (de) 1999-12-14 1999-12-14 Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
PCT/EP2000/012093 WO2001043728A1 (de) 1999-12-14 2000-12-01 Flache arzneizubereitung zur transmucosalen verabreichung von oxycodon oder einem vergleichbaren wirkstoff in der mundhöhle, für die anwendung in der schmerztherapie und suchttherapie

Publications (1)

Publication Number Publication Date
IL150127A0 true IL150127A0 (en) 2002-12-01

Family

ID=7932547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15012700A IL150127A0 (en) 1999-12-14 2000-12-01 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy

Country Status (18)

Country Link
US (1) US20040024003A1 (xx)
EP (1) EP1239847A1 (xx)
JP (1) JP2003516961A (xx)
KR (1) KR100597806B1 (xx)
CN (1) CN1407889A (xx)
AR (1) AR027902A1 (xx)
AU (1) AU781946B2 (xx)
BR (1) BR0016504A (xx)
CA (1) CA2393838A1 (xx)
CZ (1) CZ20022063A3 (xx)
DE (1) DE19960154A1 (xx)
HU (1) HUP0203733A2 (xx)
IL (1) IL150127A0 (xx)
MX (1) MXPA02005857A (xx)
PL (1) PL355816A1 (xx)
RU (1) RU2002115277A (xx)
WO (1) WO2001043728A1 (xx)
ZA (1) ZA200204225B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
EP1519718A1 (de) * 2002-05-24 2005-04-06 AgfaPhoto GmbH Wirkstoff enthaltende, zumindest teilweise abbaubare folien und verfahren zu deren herstellung
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP2716284A3 (en) * 2003-05-28 2014-11-05 MonoSol RX LLC Polyethylene oxide-based films and drug delivery systems made herefrom
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
DE102006027794A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antihypertonie-Kombinationswafer
DE102006027793A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
AU2007275581B2 (en) * 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
CN102056578A (zh) * 2008-06-23 2011-05-11 生物递送科学国际公司 多向粘膜给药装置及使用方法
US20110269841A1 (en) * 2010-05-03 2011-11-03 Innoteq, Inc. Thin film with methadone active ingredient
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
BR112014003651B1 (pt) 2011-08-18 2022-03-29 Biodelivery Sciences International, Inc Dispositivos mucoadesivos resistentes ao mau uso para a liberação de buprenorfina
KR20210003313A (ko) * 2011-12-21 2021-01-11 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 만성 통증 완화에 이용되는 점막 관통 약물 전달 장치
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013171146A1 (en) * 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
MX2021000908A (es) * 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
EP0375689B1 (en) * 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht

Also Published As

Publication number Publication date
JP2003516961A (ja) 2003-05-20
PL355816A1 (en) 2004-05-17
AU781946B2 (en) 2005-06-23
EP1239847A1 (de) 2002-09-18
CA2393838A1 (en) 2001-06-21
RU2002115277A (ru) 2004-01-10
AU2839201A (en) 2001-06-25
BR0016504A (pt) 2002-11-05
KR20020067544A (ko) 2002-08-22
DE19960154A1 (de) 2001-07-12
HUP0203733A2 (en) 2003-05-28
US20040024003A1 (en) 2004-02-05
CN1407889A (zh) 2003-04-02
WO2001043728A1 (de) 2001-06-21
AR027902A1 (es) 2003-04-16
MXPA02005857A (es) 2002-10-23
ZA200204225B (en) 2003-03-03
KR100597806B1 (ko) 2006-07-10
CZ20022063A3 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
IL150127A0 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
EP1091732A4 (en) ORAL EFFERVESCENT MEDICATION DELIVERY SYSTEM
HK1047231A1 (en) Oral pharmaceutical forms of administration with adelayed action with tramadol
IL144730A (en) Use of statin drug in the preparation of a medicament and as a medicament for the treatment of diabetic neuropathy
EP1231864A4 (en) Tissue-Attachable Drug Applicator and Method of Use Thereof
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
IL153920A (en) Somatostatin analogues, processes for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
HRP20010655B1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
IL145559A0 (en) Tolperison-containing pharmaceutical preparation for oral administration
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
HUP0303597A3 (en) Diposable vaginal cannula for the simultaneous administration of drugs in different forms
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE
HUP0200861A3 (en) Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
HUP0102191A3 (en) Use of oxazolidinones for the preparation of a medicament for transdermal delivery
IL140854A0 (en) Use of derivatives of tetrahydropyridine (or 4-tetrahydropyridine) -butylazoles in the preparation of a medicament for the treatment of pain
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
HU0500745D0 (en) Rapidly decomposable pharmaceutical dosage form for use in oral or body cavity containing nicotine as active ingredient
GB0007788D0 (en) Method to evaluate the therapeutic and toxic effects related to drug administration
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
AU1399100A (en) Therapeutic treatment with immunogenic drugs